Table 4.

Adverse event (safety set)

Adverse event	Placebo (n = 76)	DA-8010 2.5 mg (n = 75)	DA-8010 5 mg (n = 76)	Solifenacin 5 mg (n = 75)
TEAEsa)	14 (18.42)	19 (25.33)	23 (30.26)	25 (33.33)
Dry mouth	0 (0)	4 (5.33)	10 (13.16)	8 (10.67)
Constipation	1 (1.32)	0 (0)	1 (1.32)	3 (4.00)
Nasopharyngitis	1 (1.32)	3 (4.00)	2 (2.63)	4 (5.33)
Dizziness	0 (0)	1 (1.33)	4 (5.26)	2 (2.67)
Headache	0 (0)	1 (1.33)	2 (2.63)	0 (0)
Pain in extremity	2 (2.63)	0 (0)	0 (0)	0 (0)
Dysuria	0 (0)	0 (0)	2 (2.63)	2 (2.67)
Fatigue	0 (0)	0 (0)	2 (2.63)	0 (0)
Serious TEAEs	1 (1.32)	1 (1.33)	0 (0)	1 (1.33)
ADRs	3 (3.95)	5 (6.67)	14 (18.42)	13 (17.33)
Serious ADRs	0 (0)	0 (0)	0 (0)	0 (0)

Values are presented as number (%).

TEAE, treatment-emergent adverse event; ADR, adverse drug reaction.

^a)Only items with incidence rate ≥2% in at least one treatment group were listed.